Dashboard
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 35.18%
- Healthy long term growth as Net Sales has grown by an annual rate of 157.83% and Operating profit at 443.36%
- Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 17.18
Stock DNA
Pharmaceuticals & Biotechnology
AED 877,635 Million (Large Cap)
46.00
NA
0.00%
-0.36
13.80%
6.28
Total Returns (Price + Dividend) 
International Holding Co. PJSC for the last several years.
Risk Adjusted Returns v/s 
News
International Holding Co. PJSC Reports Strong Financial Metrics Amid Flat Performance
International Holding Co. PJSC has recently reported its financial performance for the quarter ending June 2025, showcasing a mix of stability and growth in key areas. Despite a flat overall performance, the company achieved notable highs in several financial metrics, indicating resilience in its operations.
The operating cash flow for the year reached an impressive AED 22,201.94 MM, marking a significant achievement for the company. This figure reflects the company's ability to generate cash from its core operations, which is crucial for sustaining growth and funding future initiatives.
Additionally, International Holding Co. PJSC reported a pre-tax profit of AED 6,441.23 MM for the quarter, further underscoring its profitability. The net profit for the same period was recorded at AED 3,505.29 MM, demonstrating the company's effective management of expen...
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot
Shareholding Compare (%holding) 
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 22.54% vs 73.73% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 55.34% vs -29.80% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 54.20% vs 19.77% in Dec 2023
YoY Growth in year ended Dec 2024 is -22.01% vs 1.18% in Dec 2023






